TB Notes Newsletter
No. 3, 2012
NEW CDC PUBLICATIONS
Ahuja SD, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9(8): e1001300. doi:10.1371/journal.pmed.1001300.
Althomsons SP, Cegielski JP. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough. Int J Tuberc Lung Dis 2012 August 2 (e-publication ahead of print); http://dx.doi.org/10.5588/ijtld.11.0812.
Bloss E, Chan P-C, Cheng N-W, Wang K-F, Yang S-L, Cegielski P. Increasing directly observed therapy related to improved tuberculosis treatment outcomes in Taiwan. Int J Tuberc Lung Dis 2012; 16(4):462–467; http://dx.doi.org/10.5588/ijtld.11.0121
Bloss E, Makombe R, Kip E, Smit M, Chirenda J, Gammino VM, Creek T, Oeltmann JE. Lessons learned during tuberculosis screening in public medical clinics in Francistown, Botswana. [Notes from the field.] Int J Tuberc Lung Dis 2012; e-publication ahead of print June 6, 2012; http://dx.doi.org/10.5588/ijtld.11.0736.
Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD and Haley CA. Moving toward tuberculosis elimination implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012 Aug 1; 186 (3): 273-279.
Cain KP, Varma JK. Finding tuberculosis at the first encounter with HIV care: don't miss the opportunity to save a life. Int J Tuberc Lung Dis 2012 Sep;16(9):1138.
Cavanaugh JS, Kazennyy BY, Nguyen ML, Kiryanova EV, Vitek E, Khorosheva TM, Nemtsova E, Cegielski JP. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002–2005. Int J Tuberc Lung Dis 2012; e-publication ahead of print June 11, 2012; http://dx.doi.org/10.5588/ijtld.11.0696.
Cavanaugh JS, Powell K, Renwick OJ, Davis KL, Hilliard A, Benjamin C, Mitruka K. An outbreak of tuberculosis among adults with mental illness. Am J Psychiatry. 2012 Jun 1;169(6):569-75.Chen MP, Shang N, Winston CA, Becerra JE. A Bayesian analysis of the 2009 decline in tuberculosis morbidity in the United States. Statistics in Medicine 2012 March 13 (e-pub); doi: 10.1002/sim.5340.
Cegielski JP, Arab L, Cornoni-Huntley J. Nutritional risk factors for tuberculosis among adults in the United States, 1971–1992. Am J Epidemiol 2012 [epub ahead of print]; doi: 10.1093/aje/kws007.
Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, Weiner M, McIlleron H, Kirkpatrick CMJ. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients With multi-drug resistant tuberculosis. Antimicrob Agents Chemother 2012 May 7. [Epub ahead of print.]
Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CL, Feng P-J, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW and the Tuberculosis Trials Consortium. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. J Infect Dis 2012 Jul 31; e-pub ahead of print; doi: 10.1093/infdis/jis461.
Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MID, Tupasi TE. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012 May 7 (e-pub ahead of print); http://dx.doi.org/10.5588/ijtld.11.0502.
Kim L, Heilig CM, McCarthy KD, Phanuphak N, Chheng P, Kanara N, Quy HT, Sar B, Cain KP, Varma JK. Symptom screen for identification of highly infectious tuberculosis in people living with HIV in Southeast Asia. J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):519-524.
Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012 Sep;92(5):397-403. Epub 2012 Jul 10.
LoBue PA, Castro KG. Is it time to replace the tuberculin skin test with a blood test? JAMA 2012;308:241-2.
Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE (2012) New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional genetic analysis of gyrA and gyrB mutations. PLoS ONE 7(6): e39754. doi:10.1371/journal.pone.0039754
Mitruka K, Winston CA, Navin TR. Predictors of failure in timely tuberculosis treatment completion, United States. IJTLD 2012 June 5 (epub ahead of publication).
Powell K, Lamb MM, Sisk MK, Federline L, Seechuk K, Lambert LA, Buff AM. Passenger contact investigation associated with a transport driver with pulmonary tuberculosis. Public Health Rep 2012;127(2):202-7.
Shah NS, Cavanaugh JS, Pratt R, Cain KP, Wells C, Laserson K, Nelson L, Smith SE. Epidemiology of smear-negative pulmonary tuberculosis in the United States, 1993–2008. Int J Tuberc Lung Dis 2012 June 28; (e-pub ahead of print); http://dx.doi.org/10.5588/ijtld.11.0794.
Tyrrell FC, Budnick GE, Elliott T, Gillim-Ross L, Hildred MV, Mahlmeister P, Parrish N, Pentella M, Vanneste J, Wang YF, Starks AM. Probability of negative Mycobacterium tuberculosis complex cultures based on time-to-detection of positive cultures: a multi-center evaluation of commercial broth-based culture systems. J Clin Microbiol. 2012 Jul 25. (e-pub ahead of print)
Winston CA, Mitruka K. Treatment duration for patients with drug-resistant tuberculosis, United States [letter]. Emerg Infect Dis 2012 June; http://dx.doi.org/10.3201/eid1807.120261.
Contact Us:
- Centers for Disease Control and Prevention
Division of Tuberculosis Elimination (DTBE)
1600 Clifton Rd., NE
MS E10
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - cdcinfo@cdc.gov
